FDA pharmacologic class
CTLA-4-directed Blocking Antibody
2 medicines are in FDA's class of ctla-4-directed blocking antibodies: ipilimumab (Yervoy) and tremelimumab (Imjudo). 0 of the 2 are listed from generic labelers (FDA NDC Directory, October 8, 2026).
Which medicines are ctla-4-directed blocking antibody?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Ipilimumab | Yervoy | none listed | n/a | No | No current entry | 0 |
| Tremelimumab | Imjudo | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)